REFERENCES
1 – Civil Protection Department of the Italian Government:http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1(Accessed the 18th June 2020)
2 - Pennington E. Asthma increases risk of severity of COVID-19. Cleve
Clin J Med. 2020. doi: 10.3949/ccjm.87a.ccc002.
3 - Busse WW, Lemanske RF Jr, Gern JE. Role of viral respiratory
infections in asthma and asthma exacerbations. Lancet. 2010 Sep
4;376(9743):826-34
4 - Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic
respiratory diseases or their treatment affect the risk of SARS-CoV-2
infection? Lancet Respir Med. 2020;8(5):436-438.
5 - Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock
IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P,
Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN,
Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on
definition, evaluation and treatment of severe asthma. Eur Respir J.
2014 Feb;43(2):343-73.
6 - Heffler E, Blasi F, Latorre M, Menzella F, Paggiaro P, Pelaia G,
Senna G, Canonica GW; SANI Network. The Severe Asthma Network in Italy:
Findings and Perspectives. J Allergy Clin Immunol Pract.
2019;7(5):1462-1468.
7 - Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA,
Visness CM, Durham SR, Larson D, Esnault S, Ober C, Gergen PJ, Becker P,
Togias A, Gern JE, Altman MC. Association of respiratory allergy,
asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin
Immunol. 2020. doi: 10.1016/j.jaci.2020.04.009.
8 - Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery
MT, Woodruff PG, Mauger DT, Erzurum SC, Johansson MW, Denlinger LC,
Jarjour NN, Castro M, Hastie AT, Moore W, Ortega VE, Bleecker ER, Wenzel
SE, Israel E, Levy BD, Seibold MA, Fahy JV; National Heart, Lung, and
Blood Institute Severe Asthma Research Program-3 Investigators. COVID-19
Related Genes in Sputum Cells in Asthma: Relationship to Demographic
Features and Corticosteroids. Am J Respir Crit Care Med. 2020. doi:
10.1164/rccm.202003-0821OC.
9 - Jesenak M, Banovcin P, Diamant Z. COVID‐19, chronic inflammatory
respiratory diseases and eosinophils – Observationsfrom reported
clinical case series. Allergy 2020. doi:10.1111/all.14353
Enrico Heffler 1,2; Aikaterini Detoraki3; Marco Contoli 4; Alberto Papi4; Giovanni Paoletti 1,2; Giacomo
Malipiero 1; Luisa Brussino 5;
Claudia Crimi 6; Daniela Morrone 7;
Marianna Padovani 4; Giuseppe Guida8; Alberto Giovanni Gerli 9; Stefano
Centanni 10; Gianenrico Senna 11;
Pierluigi Paggiaro 12; Francesco Blasi13,14; Giorgio Walter Canonica 1,2on behalf of SANI Working Group *
1 Personalized Medicine, Asthma and Allergy -
Humanitas Clinical and Research Center IRCCS - Rozzano (MI), Italy
2 Department of Biomedical Sciences – Humanitas
University – Pieve Emanuele (MI), Italy
3 Department of Internal Medicine, Clinical
Immunology, Clinical Pathology and Infectious Disease, Azienda
Ospedaliera Universitaria Federico II, Napoli, Italy.
4 Department of Morphology, Surgery and Experimental
Medicine - University of Ferrara – Ferrara, Italy.
5 Department of Medical Sciences, AO Ordine Mauriziano
Umberto I – University of Torino - Torino, Italy.
6 Department of Clinical and Experimental Medicine -
University of Catania - Catania, Italy.
7 Severe Asthma Network in Italy (SANI) infrastructure
– Milano, Italy
8 Allergy and Pneumology Unit - A.O. S. Croce e Carle
– Cuneo, Italy.
9 Management Engineering Tourbillon Tech srl - Padova,
Italy.
10 Respiratory Unit, ASST Santi Paolo e Carlo, San
Paolo Hospital, Department of Health Sciences – University of Milano -
Milano, Italy.
11 Asthma Center and Allergy Unit - Verona University
Hospital - Verona, Italy.
12 Department of Surgery, Medicine, Molecular Biology
and Critical Care - University of Pisa - Pisa, Italy.
13 Internal Medicine Department – Respiratory Unit
and Adult Cystic Fibrosis Center – Fondazione IRCCS Cà Granda Ospedale
Maggiore Policlinico - Milano, Italy.
14 Department of Pathophysiology and Transplantation
– University of Milano – Milano, Italy
* SANI Working Group: Bonavia M., Bucca C., Caiaffa
MF., Calabrese C., Camiciottoli G., Caruso C., Conte ME., Corsico AG.,
Cosmi L., Costantino MT., Crimi N., D’Alò S., D’Amato M., Del Giacco S.,
Farsi A., Favero E., Foschino BMP., Guarnieri G., Lo Cicero S., Lombardi
C., Macchia L., Mazza F., Menzella F., Milanese M., Montuschi P.,
Montagni M., Nucera E., Parente R., Passalacqua G., Patella V., Pelaia
G., Pini L., Puggioni F., Ricciardi L., Ricciardolo FLM., Richeldi L.,
Ridolo E., Rolla G., Santus P., Scichilone N., Solidoro P., Spadaro G.,
Vianello A., Viviano V., Yacoub MR., Zappa MC.
Corresponding Author:
Prof. Enrico Heffler
Personalized Medicine, Asthma and Allergy
Istituto Clinico Humanitas
Via Alessandro Manzoni 56
20089 – Rozzano (MI) – Italy
Tel: +39 0282247013
Fax: + 39 0282246484
Email:enrico.heffler@hunimed.eu
Conflict of interest statements:
- Enrico Heffler reports participation to advisory boards and personal
fees from AstraZeneca, Sanofi, GSK, Novartis, Circassia, Nestlè
Purina, Boheringer Ingheleim, Valeas, outside the submitted work;
- Aikaterini Detoraki does not have any conflict of interest to report
- Marco Contoli reports grants from Chiesi, University of Ferrara –
Italy, personal fees from Chiesi, AstraZeneca, Boehringer Ingelheim,
Alk-Abello, GlaxoSmithKline, Novartis, Zambon, outside the submitted
work
- Alberto Papi reports grants, grants, personal fees and non-financial
support from AstraZeneca, Menarini, grants, personal fees,
non-financial support and other from Boehringer Ingelheim, Chiesi
Farmaceutici, TEVA, personal fees, non-financial support and other
from GlaxoSmithKline, Mundipharma, Zambon, Novartis, Sanofi/Regeneron,
personal fees from Roche, Edmondpharma, grants from Fondazione
Maugeri, Fondazione Chiesi, outside the submitted work.
- Giovanni Paoletti does not have any conflict of interest to report
- Giacomo Malipiero does not have any conflict of interest to report
- Luisa Brussino does not have any conflict of interest to report
- Claudia Crimi reports personal fees from Menarini.
- Daniela Morrone does not have any conflict of interest to report
- Marianna Padovani does not have any conflict of interest to report
- Giuseppe Guida does not have any conflict of interest to report
- Alberto Giovanni Gerli does not have any conflict of interest to
report
- Stefano Centanni reports personal fees from GLAXOSMITHKLINE, NOVARTIS,
MENARINI SPA, GUIDOTTI MALESCI, and grants and personal fees from
CHIESI SPA, ASTRA ZENECA, VALEAS, BOEHRINGER INGELHEIM, outside the
submitted work
- Gianenrico Senna does not have any conflict of interest to report
- Pierluigi Paggiaro reports grants and personal fees from AstraZeneca,
Chiesi, Novartis and Sanofi, and personal fees from GlaxoSmithKline,
Guidotti, Mundipharma, outside the submitted work
- Francesco Blasi reports grants and personal fees from Astrazeneca,
Chiesi, GSK, Pfizer and Insmed, grants from Bayer, and personal fees
from Guidotti, Grifols, Menarini, Mundipharma, Novartis and Zambon,
outside the submitted work
- Giorgio Walter Canonica reports grants as well as lecture or advisory
board fees from: A. Menarini, Alk-Abello, Allergy Therapeutics,
AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, Genentech,
Guidotti-Malesci, Glaxo Smith Kline, Hal Allergy, Mylan, Merck,
Mundipharma, Novartis, Regeneron, Sanofi-Aventis, Sanofi-Genzyme,
StallergenesGreer, UCB pharma, Uriach Pharma, Valeas, ViborPharma
Funding statement: SANI is supported through unrestricted grants by
AstraZeneca, Glaxo Smith Kline, Novartis & Sanofi Genzyme
Aknowledgements :
We are grateful to Silvia Rabotti, Concetta Sirena & the SANI staff for
the invaluable work in managing the network.